MedTrace Logo

Candesartan's Effects on Alzheimer's Disease And Related Biomarkers

NCT02646982 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2022-12-01

Study results available
· View outcomes & findings →

Summary

This study is intended to investigate the safety of candesartan, a blood pressure medication, in non-hypertensive individuals who have mild cognitive impairment (MCI) due to Alzheimer's disease and its effect on disease biomarkers.

Conditions

Interventions

DRUG

Placebo

A matched placebo will be given once daily for 12 months.

DRUG

Candesartan

Candesartan will be started at 8 mg orally, once daily. The dose will be increased in 2 week increments to 16 mg and 32 mg orally, once a day, as long as SBP\>100 mm Hg, DBP\>40 mm Hg and there are no reported symptoms of hypotension (dizziness or weakness). Candesartan will be given for a total of 12 months.

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • Emory University

    lead OTHER

Principal Investigators

  • Ihab Hajjar, MD · Emory University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2020-08-17
Completion
2020-08-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02646982 on ClinicalTrials.gov